ESH Video

#ESHAL2024 HAVE YOU REGISTERED YET?

November 08, 2023

 

ESH 4th How to Diagnose and Treat

ACUTE LEUKAEMIAS

 

March 1-3, 2024

Stockholm, Sweden

#ESHAL2024

 

 


 

Have you registered yet?
The Conference is just a few months away:
proceed now & join us in Sweden in March!

 

 


 

CALL FOR ABSTRACT & CLINICAL CASE:
DEADLINE: DECEMBER 14th, 2023

Clinical cases and abstracts are eligible to be selected for an oral or a poster presentation.

 


 

About the Conference:

ESH How to Diagnose and Treat meetings are disease-specific meetings that address up to date diagnostic and clinical management which is greatly facilitated by and discussion of real clinical cases. Intensive interaction between the speakers and participants will be helpful in spreading knowledge.

Novel and still evolving insights into the biology and diagnosis of acute myeloid leukaemias (AMLs) and acute lymphoblastic leukaemias (ALL), has resulted in new drug approvals and new therapeutic options to treat newly-diagnosed as well as relapsed/refractory disease. Recently updates on prognostication and classification of acute leukemias have been published which will be discussed in various sessions

The programme of this “How to Diagnose and Treat: Acute Leukaemias” includes genomic analysis and cutting-edge technics in routine diagnosis, targeted therapies and standard of care treatments allogeneic haematopoietic stem cell (HSCT) transplantation and innovative immunotherapies, as well as diagnosis and management of rare acute leukaemia subtypes. Clonal hematopoiesis will be covered in detail. Novel trial designs instrumental for smarter drug development is discussed in a separate session.

 


 

Conference main scientific topics:

• Diagnosis and treatment of rare diseases
• Novel treatments
• Dilemmas in AML
• Debate: MRD conversion before alloSCT
• Innovative trial designs to accelerate advances in leukaemia
• Immunotherapy in AML and ALL
• VenAza or intensive chemo as 1L treatment before allo HCT
• Debate: Transplant is no longer first line approach to Ph+ ALL
• Leukaemia treatment challenges
• Clonal haematopoiesis and germline predisposition

 

To read the preliminary programme, click here!
For more information, click here!